Meeting
2011 ASCO Annual Meeting
Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results.
Authors
Elisabeth De Vries
Department of Medical Oncology, University Medical
Elisabeth De Vries , Lowell Anthony , Lucas Sideris , Li-Tzong Chen , Jeremie Lebrec , Zenta Tsuchihashi , Robert Winkler , James Yao , Kjell Oberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Other
Clinical Trial Registration Number
NCT00510068
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10624)
Abstract #
10624
Poster Bd #
35A
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3).
First Author: Jonathan Strosberg
Poster
2012 ASCO Annual Meeting
Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET).
First Author: James C. Yao
Poster
2011 ASCO Annual Meeting
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.
First Author: Manisha Shah
Poster
2021 ASCO Annual Meeting
Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).
First Author: Xianjun Yu